– The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price
– Inclisiran, The Medicines Company’s investigational, innovative, potent twice-annual therapy to lower LDL cholesterol, has potential to transform treatment of cardiovascular disease
– Transaction expected to be completed in first quarter of 2020
More: https://www.themedicinescompany.com/investor/pr/4241119/